Toxic epidermal necrosis - Epidermalibus Toxicus Necrosishttps://en.wikipedia.org/wiki/Toxic_epidermal_necrolysis
Epidermalibus Toxicus Necrosis (Toxic epidermal necrosis) genus est reactionis cutis gravis. Signa prima includunt febrem et symptomata fluviatilia. Paucis diebus post cutis pustula incipit et areae squamosas formans, quae sunt dolorosae. Aliquando membranae mucosae, ut os, etiam involvuntur. Complicationes includunt siccitatem, sepsim, pneumoniam et multiplicem defectum organorum.

Causa frequentissima est usus medicamentorum, ut lamotrigine, carbamazepine, allopurinol, sulfonamide antibioticum, et nevirapine. Factores periculosi includunt HIV et lupus erythematosus systemicum. Curatio typice praebetur in valetudinariis, ut in unitate combustionis vel unitate intensive curae.

○ Curatio
Gravis hic morbus est; si labia tua vel os afficiuntur vel cutis tua pustulata est, medicum quam primum videas.
Medicamina suspecta suspendenda sunt (v.g. antibiotica, non‑steroidales medicamenta inflammationis anti‑inflammatoriae).

☆ In anno 2022 Stiftung Warentest ex Germania provenit, satisfactio consumptoria cum ModelDerm paulo minus fuit quam cum consultationibus telemedicinis solutis.
  • Epidermalibus Toxicus Necrosis (Toxic epidermal necrosis) damnum cutis propria est
  • TENS die 10
  • Necrolysis epidermalis toxica
  • Maculae praemature celeriter progredi possunt ut intra paucos dies totum corpus involvat.
References Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management 34577817 
NIH
Stevens-Johnson Syndrome (SJS) et Toxic Epidermal Necrolysis (TEN) sunt rarae conditiones, in quibus cutis amplam necrosim et effusionem experitur. In curatione, cyclosporinum maxime efficax est pro SJS, dum combinatio immunoglobulin intravenous (IVIg) et corticosteroides optime pro casibus SJS et TEN operatur.
Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare diseases that are characterized by widespread epidermal necrosis and sloughing of skin. Regarding treatment, cyclosporine is the most effective therapy for the treatment of SJS, and a combination of intravenous immunoglobulin (IVIg) and corticosteroids is most effective for SJS/TEN overlap and TEN.
 Toxic Epidermal Necrolysis: A Review of Past and Present Therapeutic Approaches 36469487
Toxic epidermal necrolysis (TEN) gravis reactiones cutis causatur a quibusdam medicamentis et activitate immuna, quae in amplissima necrolisi strati exterioris (epidermis) manifestatur, plus quam 30 % superficiei corporis afficiens. TEN habet mortalitatem plus quam viginti percentum, saepe ob infectiones et difficultates respirandi. Suspenditur medicamentum quod reactionem provocavit, praebentur curæ de supportu, et curationes adjuvantēs adhibentur ad eventum emendandum. Recentibus studiis demonstraverunt medicamenta sicut cyclosporinum, inhibitores factoris necrosisis tumoris α, et combinatio globulorum immunium intravenosarum cum corticosteroides posse esse utiles, fundata in iudiciis moderatis et multiplicibus analysibus studiorum randomizatorum.
Toxic epidermal necrolysis (TEN) is a serious skin reaction caused by certain medications and immune system activity, resulting in large-scale detachment of the outer skin layer (epidermis), affecting more than 30% of the body's surface. TEN has a mortality rate of over 20%, often due to infections and breathing difficulties. Stopping the medication causing the reaction, providing supportive care, and using additional treatments can improve the outcome. Recent studies have shown that drugs like cyclosporine, tumor necrosis factor alpha inhibitors, and a combination of intravenous immune globulin and corticosteroids can be helpful, based on randomized controlled trials and analyses of multiple studies.
 Toxic Epidermal Necrolysis and Steven–Johnson Syndrome: A Comprehensive Review 32520664 
NIH
Recent Advances: There is improved understanding of pain and morbidity with regard to the type and frequency of dressing changes. More modern dressings, such as nanocrystalline, are currently favored as they may be kept in situ for longer periods. The most recent evidence on systemic agents, such as corticosteroids and cyclosporine, and novel treatments, are also discussed.